A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Phase 2

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Sponsor:

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

Code:

NCT06001177

Conditions

Celiac Disease

Coeliac Disease

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

KAN-101

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information